Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
Q4 2025 vs. Q3 2025
How the institutions holding Calidi Biotherapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 22 | 27 | +5 |
| Shares | 232.5K | 448.3K | +215.8K (+92.8%) |
| Value | $353.6K | $524.7K | +$171.1K (+48.4%) |
New holders (8)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DRW Securities, LLC | 147,767 | $172.9K | 0.01% |
| Virtu Financial LLC | 21,243 | $25.0K | 0.00% |
| Northern Trust Corp | 17,758 | $20.8K | 0.00% |
| Jane Street Group, LLC | 11,491 | $13.4K | 0.00% |
| Farther Finance Advisors, LLC | 10,000 | $11.7K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,774 | $3.25K | 0.00% |
| Northwestern Mutual Wealth Management Co | 28 | $33 | 0.00% |
| Citigroup Inc | 1 | $1 | 0.00% |
Sold out (3)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Warberg Asset Management LLC | 18,705 | $28.4K |
| Royal Bank of Canada | 417 | $1.00K |
| JPMorgan Chase & Co | 9 | $14 |